Prof. Gregory Grabowski Cincinnati Children's Hospital Medical Center, USA

Dr. Grabowski received his M.D. from the University of Minnesota where he also completed his residency in Pediatrics and fellowship training in Human Genetics. He then established his research and clinical programs at the same institution before moving to New York City and the Mount Sinai School of Medicine in... read more1979. There he developed the world’s largest clinic for patients afflicted with Gaucher disease and other lysosomal diseases. He established basic research and diagnostic laboratories for genetic diseases as well as the first treatment center for enzyme therapy in Gaucher disease. Following these highly productive 13.5 years, he was recruited to Cincinnati where he was the A. Graeme Mitchell Chair of Human Genetics, and Director of Human Genetics (DHG) at the Children’s Hospital Research Foundation. He also was Professor in the Departments of Molecular Genetics and Biochemistry, and Pediatrics, at the University of Cincinnati College of Medicine. In these positions, he formed the clinical, educational, diagnostic, and research infrastructure for the DHG and its ~30 faculty. During his research career, he has published over 320 scholarly works on the basic and clinical sciences of lysosomal storage and genetic diseases, while maintaining active clinical and treatment programs genetic diseases. He has continuously served on committees of the National Institutes of Health, the national and state governments, and many philanthropic (through the Project Hope Gaucher Disease Initiative) and patient foundations. He is a member of the American Society for Clinical Investigation, the American Association of Physicians, the editorial board of Molecular Genetics and Metabolism, and other societies. He has served as President of the Society for Inherited Metabolic Diseases. His continuing passion has been to discover and develop specific treatments for inherited diseases. In 2014, after 21.5 years at Cincinnati Children’s Hospital Medical Center, Dr. Grabowski joined Synageva BioPharma, a biopharmaceutical company, as their Chief Scientific Officer to continue his pursuit of therapies for rare, devastating, inherited diseases. After the acquisition of Synageva by Alexion in June 2015, he now has the positions of Professor Emeritus of Pediatrics and Genetics at the Cincinnati Children’s Hospital Research Foundation, and is a Consultant for and/or member of Scientific Advisory Boards for several biotech companies, and is Chief Scientific Officer of Kiniksa Pharmaceuticals.